Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Law’s Craig Nard discusses the importance of intellectual property to startup tech companies
- Tinkham Veale University Center video wall’s creator boasts impressive artistic record
- Nursing school to launch new MOOC on health care quality improvement
- Today’s Constitution Day forum to focus on executive overreach
- First Salon Series event to feature panel discussion on gender equality